SCHEMBL6600439

SCHEMBL6600439

COCCCOc1ccnc(CS(=O)(=O)c2nc3ccccc3[nH]2)c1C.[Na]

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.62
KMT2A Q03164 5/20 0.62
WDR5 P61964 4/20 0.62
ALDH1A1 P00352 4/20 0.62
LMNA P02545 4/20 0.62
ENGASE Q8NFI3 3/20 0.62
MAPT P10636 3/20 0.62
DDAH1 O94760 2/20 0.62
ADORA3 P0DMS8 2/20 0.62
HPGD P15428 2/20 0.62
TBXA2R P21731 2/20 0.62
NPY1R P25929 2/20 0.62
ADORA1 P30542 2/20 0.62
OPRM1 P35372 2/20 0.62
HTR3A P46098 2/20 0.62
FASN P49327 2/20 0.62
SARM1 Q6SZW1 2/20 0.62
ABCG2 Q9UNQ0 2/20 0.62
HTR1A P08908 1/20 0.62
IDE P14735 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1307379 0.99 KMT2A (0.63) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL30905609 0.99 KMT2A (0.63) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL6600434 0.98 KMT2A (0.62) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL10121508 0.88 KMT2A (0.62) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL23988420 0.87 CYP2C9 (0.51) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL2851052 0.85 KMT2A (0.59) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL23988519 0.85 CYP2C9 (0.53) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL5414007 0.84 KMT2A (0.60) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL23988509 0.84 CYP2C9 (0.47) CYP2C9KMT2AWDR5ALDH1A1LMNA
SCHEMBL2851048 0.83 KMT2A (0.59) CYP2C9KMT2AWDR5ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112521370-B Radioisotope carbon-14labeled D-rabeprazole sodium and synthetic method thereof 浙江爱索拓科技有限公司 2021-11-02 CN disclosed
CN-112521370-A Radioisotope carbon-14labeled D-rabeprazole sodium and synthetic method thereof 上海启甄环境科技有限公司 2021-03-19 CN disclosed
US-20040180935-A1 Crystalline form Z of rabeprazole sodium and process for preparation thereof DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S LABORATORIES INC. 2004-09-16 US disclosed
EP-1452533-A1 Crystalline form Z of rabeprazole sodium and process for preparation thereof Dr. Reddy's Laboratories Ltd. (IN) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180935-A1 Crystalline form Z of rabeprazole sodium and process for preparation thereof CTSZ, RAB35, RAB14 CYP2C9 61/4885KMT2A 3535/4885WDR5 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.